Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiac Arrhythmia & Safety Pharmacology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCNE1 drug discovery. As an ion channel modulatory subunit, native conformational presentation is paramount. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length Membrane Protein) | KCNE1 full-length membrane protein, HEK293 expressed with native glycosylation, >95% purity, endotoxin <1 EU/μg. Sequence verified. | View KCNE1 Products |
| Gene Delivery (Lentivirus) | KCNE1 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell lines preserving native conformation with KCNQ1. Sequence verified, high titer (>10⁸ TU/ml). | View KCNE1 Products |
| Benchmark Antibody | Anti-KCNE1 recombinant positive control for expression validation (Flow Cytometry, Western Blot). | View KCNE1 Products |
| Validator (siRNA) | KCNE1 siRNA Set for knockdown verification and specificity control in functional assays. | View KCNE1 Products |
| Related Target A: KCNQ1 | Pore-forming α-subunit; co-expression essential for functional IKs channel. Lentivirus also available. | View KCNQ1 Products |
| Related Target B: KCNE2 | MiRP family member; critical for selectivity and off-target counter-screening. | View KCNE2 Products |
| Related Target C: KCNH2 (hERG) | Mandatory cardiac safety counter-screen; co-expression panel for CiPA compliance. | View KCNH2 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage |
|---|---|
| Functional IKs Channel Reconstitution | Human KCNE1+KCNQ1 co-expression lentivirus system; bicistronic or mix-infection ensures correct stoichiometry (4:4). |
| Cross-species Cardiac Safety Evaluation | Human/Mouse/Cyno ortholog proteins and lentivirus available; endotoxin controlled (<1 EU/μg). |
| KCNE Family Selectivity (KCNE1 vs KCNE2/3) | Full panel of sequence-verified KCNE family ORFs and extracellular domains for profiling. |
| Assay Specificity & False Positive Control | Validated siRNA included for background baseline verification; clinical benchmark antibodies for structural calibration. |
| LQT5 Mutant Analysis | Disease mutant lentivirus (e.g., D76N, D85N, S74L) available; sequence verified for trafficking and functional rescue studies. |
Live KCNE1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
KCNE1 (minK) is the essential β-subunit of the cardiac slow delayed rectifier potassium current (IKs), forming a functional heteromeric complex with KCNQ1 (Kv7.1). Loss-of-function mutations in KCNE1 cause Long QT Syndrome Type 5 (LQT5) and Jervell and Lange-Nielsen Syndrome Type 2 (JLNS2). Key mutations include p.Arg98Trp (JLNS2, impairs glycosylation at N-5, dbSNP:rs28933384) and two LQT5-associated variants of uncertain significance (rs199473348, rs144917638). The therapeutic landscape is shifting from broad-spectrum antiarrhythmics toward precision small molecule IKs activators, gene therapies targeting specific mutations, and comprehensive safety pharmacology (CiPA initiative). The next wave focuses on mutation-specific pharmacochaperones and AAV-based gene editing for inherited channelopathies. Demand for high-fidelity KCNE1/KCNQ1 assay systems is accelerating, driven by the need for native conformational presentation and accurate heteromeric assembly.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | AstraZeneca, Sanofi | LQT5, JLNS | Functional electrophysiology with co-expressed KCNE1/KCNQ1 stable cell lines (Lentivirus-based). |
| Small Molecule Inhibitors | Bayer, Novartis | Atrial Fibrillation | Selectivity screening against KCNQ1/KCNE2 counter-targets. |
| Gene Therapy / ASO | Precision Biosciences, Editas, BioMarin | Genetic Arrhythmias (LQT5) | Knockdown validation (siRNA) and trafficking analysis using mutant constructs. |
| Safety Pharmacology (CiPA) | Charles River, IQVIA, Eurofins | Drug-induced arrhythmia risk | Automated patch clamp with heteromeric channel complexes; KCNE1/KCNQ1 vs. hERG panel. |
| Peptide Modulators | Academic spin-offs | Cardiovascular Disease | Affinity binding assays using high-purity ECD recombinant proteins. |